Table 3.
Medical history of participants at enrolment into the CoLTART study by sex and site
| Medical condition | All combined | Entebbe site | Kyamulibwa site | ||||
|---|---|---|---|---|---|---|---|
| n (%) | All, n (%) | Sex | All, n (%) | Sex | |||
| Females, n (%) | Males, n (%) | Females, n (%) | Males, n (%) | ||||
| All | 1095 | 666 | 459 (68.9) | 207 (31.1) | 429 | 252 (58.7) | 177 (41.3) |
| Hypertension history | |||||||
| Never had hypertension | 936 (85.5) | 556 (83.5) | 378 (82.4) | 178 (86.0) | 380 (88.6) | 222 (88.1) | 158 (89.3) |
| Ever had hypertension | 159 (14.5) | 110 (16.5) | 81 (17.6) | 29 (14.0) | 49 (11.4) | 30 (11.9) | 19 (10.7) |
| Diabetes mellitus historya | |||||||
| No known diabetes mellitus | 1067 (97.9) | 645 (97.3) | 445 (97.4) | 200 (97.1) | 422 (98.8) | 248 (98.8) | 174 (98.9) |
| Known diabetes mellitus | 23 (2.1) | 18 (2.7) | 12 (2.6) | 6 (2.9) | 5 (1.2) | 3 (1.2) | 2 (1.1) |
| Renal disease historyb | |||||||
| No renal disease | 1087 (99.4) | 659 (99.1) | 456 (99.3) | 203 (98.5) | 428 (99.8) | 252 (100.0) | 176 (99.4) |
| Known renal disease | 7 (0.6) | 6 (0.9) | 3 (0.7) | 3 (1.5) | 1 (0.2) | 0 (0.0) | 1 (0.6) |
| ART exposure, years | |||||||
| ART naïve | 74 (6.8) | 27 (4.1) | 21 (4.6) | 6 (2.9) | 47 (11.0) | 22 (8.7) | 25 (14.1) |
| <1 years | 79 (7.2) | 13 (2.0) | 11 (2.4) | 2 (1.0) | 66 (15.4) | 35 (13.9) | 31 (17.5) |
| 1 to <5 years | 164 (15.0) | 7 (1.1) | 6 (1.3) | 1 (0.5) | 157 (36.6) | 98 (38.9) | 59 (33.3) |
| 5 to <9 years | 124 (11.3) | 15 (2.3) | 9 (2.0) | 6 (2.9) | 109 (25.4) | 65 (25.8) | 44 (24.9) |
| 9+ years | 654 (59.7) | 604 (90.7) | 412 (89.8) | 192 (92.8) | 50 (11.7) | 32 (12.7) | 18 (10.2) |
| Metabolic abnormalities study groupsc | |||||||
| Non-protease Inhibitor based ART | 785 (76.9) | 432 (67.6) | 306 (69.9) | 126 (62.7) | 353 (92.4) | 212 (92.2) | 141 (92.8) |
| Protease Inhibitor based ART | 236 (23.1) | 207 (32.4) | 132 (30.1) | 75 (37.3) | 29 (7.6) | 18 (7.8) | 11 (7.2) |
| Renal dysfunction study groupsd | |||||||
| Tenofovir containing ART | 608 (59.6) | 500 (78.3) | 337 (76.9) | 163 (81.1) | 108 (28.3) | 64 (27.8) | 44 (29.0) |
| Non-Tenofovir containing ART | 413 (40.5) | 139 (21.8) | 101 (23.1) | 38 (18.9) | 274 (71.7) | 166 (72.2) | 108 (71.1) |
| Body mass index (kg/m2)e | |||||||
| <18.5 | 114 (10.6) | 48 (7.4) | 29 (6.5) | 19 (9.4) | 66 (15.4) | 29 (11.5) | 37 (21.0) |
| 18.5–24.9 | 674 (62.8) | 365 (56.6) | 217 (49.0) | 148 (73.3) | 309 (72.2) | 175 (69.4) | 134 (76.1) |
| 25.0–29.9 | 218 (20.3) | 172 (26.7) | 140 (31.6) | 32 (15.8) | 46 (10.8) | 41 (16.3) | 5 (2.8) |
| ≥30 | 67 (6.3) | 60 (9.3) | 57 (12.9) | 3 (1.5) | 7 (1.6) | 7 (2.8) | 0 (0.0) |
| Haemoglobin (g/dl)f | |||||||
| Normal | 908 (83.3) | 570 (86.2) | 387 (85.1) | 183 (88.8) | 338 (78.8) | 199 (79.0) | 139 (78.5) |
| Abnormal | 182 (16.7) | 91 (13.8) | 68 (14.9) | 23 (11.2) | 91 (21.2) | 53 (21.0) | 38 (21.5) |
| CD4 cell counts at enrolment (cells/µl)g | |||||||
| ≤350 | 307 (30.1) | 182 (30.6) | 102 (25.2) | 80 (42.3) | 125 (29.3) | 65 (26.1) | 60 (33.9) |
| 351–500 | 327 (32.1) | 171 (28.8) | 118 (29.1) | 53 (28.0) | 156 (36.6) | 89 (35.7) | 67 (37.9) |
| 501+ | 386 (37.8) | 241 (40.6) | 185 (45.7) | 56 (29.6) | 145 (34.0) | 95 (38.2) | 50 (28.2) |
| Viral loads at enrolment (cells/ml)h | |||||||
| ≤1000 copies/ml | 823 (77.7) | 528 (81.6) | 363 (81.2) | 165 (82.5) | 295 (71.6) | 180 (75.3) | 115 (66.5) |
| >1000 copies/ml | 236 (22.3) | 119 (18.4) | 84 (18.8) | 35 (17.5) | 117 (28.4) | 59 (24.7) | 58 (33.5) |
Number of participants with missing data: aDiabetes mellitus history—5, bRenal disease history—1, cMetabolic abnormalities study groups—74 patients who were ART naïve at enrolment, dRenal dysfunction study groups—74 patients who were ART naïve at enrolment, eBody Mass Index—22, fHaemoglobin—5, gCD4 cell counts at enrolment—75, hViral loads at enrolment-36; the 1059 included the 74 ART naïve individuals pending ART initiation
NNRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor